{"title":"老年患者急性扁桃体咽炎的治疗:复杂局部治疗的几个方面。","authors":"T Yu Vladimirova, A B Martynova","doi":"10.17116/otorino20259004119","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Infectious and inflammatory diseases of the pharynx remain the focus of attention of physicians of many specialties due to their high prevalence and social significance.</p><p><strong>Material and methods: </strong>The main group (<i>n</i>=30, mean age 68.9±5.6 years) was prescribed Dorithricin for resorption, 1 tablet every 3 hours, no more than 6 tablets per day for 6 days. The control group (<i>n</i>=30, mean age 68.3±4.7 years) was recommended treatment with antiviral and antipyretic agents.</p><p><strong>Results: </strong>By the 2nd visit, 16.7% of elderly patients experienced complete relief of sore throat, and no cases of high-intensity sore throat were recorded. By the 3rd day of treatment, the proportion of such patients increased significantly, amounting to 43.3%, and by the end of treatment, 96.7% of patients taking Dorithricin had no sore throat. The most significant changes during treatment were noted in relation to such additional symptoms as discomfort when swallowing and dysphagia. When assessing the pharyngoscopic picture, statistically significant differences were noted between the groups by the 2nd visit in relation to hyperemia of the oropharyngeal mucosa (<i>p</i>=0.048), the severity of edema of the oropharyngeal mucosa (<i>p</i>=0.043). Patients who received Dorithricin rated their satisfaction with the treatment as satisfied and extremely satisfied in 33.3% and 66.7%, the assessment of doctors was comparable.</p><p><strong>Conclusion: </strong>This study may contribute to the confidence of physicians in prescribing the complex drug Dorithricin, which includes substances that affect all key components of the pathogenesis of acute tonsillopharyngitis in elderly patients and increase patient satisfaction and expectations.</p>","PeriodicalId":23575,"journal":{"name":"Vestnik otorinolaringologii","volume":"90 4","pages":"19-26"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Treatment of acute tonsillopharyngitis in elderly patients: aspects of complex topical therapy].\",\"authors\":\"T Yu Vladimirova, A B Martynova\",\"doi\":\"10.17116/otorino20259004119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Infectious and inflammatory diseases of the pharynx remain the focus of attention of physicians of many specialties due to their high prevalence and social significance.</p><p><strong>Material and methods: </strong>The main group (<i>n</i>=30, mean age 68.9±5.6 years) was prescribed Dorithricin for resorption, 1 tablet every 3 hours, no more than 6 tablets per day for 6 days. The control group (<i>n</i>=30, mean age 68.3±4.7 years) was recommended treatment with antiviral and antipyretic agents.</p><p><strong>Results: </strong>By the 2nd visit, 16.7% of elderly patients experienced complete relief of sore throat, and no cases of high-intensity sore throat were recorded. By the 3rd day of treatment, the proportion of such patients increased significantly, amounting to 43.3%, and by the end of treatment, 96.7% of patients taking Dorithricin had no sore throat. The most significant changes during treatment were noted in relation to such additional symptoms as discomfort when swallowing and dysphagia. When assessing the pharyngoscopic picture, statistically significant differences were noted between the groups by the 2nd visit in relation to hyperemia of the oropharyngeal mucosa (<i>p</i>=0.048), the severity of edema of the oropharyngeal mucosa (<i>p</i>=0.043). Patients who received Dorithricin rated their satisfaction with the treatment as satisfied and extremely satisfied in 33.3% and 66.7%, the assessment of doctors was comparable.</p><p><strong>Conclusion: </strong>This study may contribute to the confidence of physicians in prescribing the complex drug Dorithricin, which includes substances that affect all key components of the pathogenesis of acute tonsillopharyngitis in elderly patients and increase patient satisfaction and expectations.</p>\",\"PeriodicalId\":23575,\"journal\":{\"name\":\"Vestnik otorinolaringologii\",\"volume\":\"90 4\",\"pages\":\"19-26\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vestnik otorinolaringologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17116/otorino20259004119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik otorinolaringologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/otorino20259004119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
咽部感染性和炎症性疾病由于其高患病率和社会意义,一直是许多专科医生关注的焦点。材料与方法:主要组患者30例,平均年龄(68.9±5.6)岁,口服甲氧甲苷促进吸收,每3 h 1片,每天不超过6片,连用6 d。对照组患者30例,平均年龄68.3±4.7岁,推荐使用抗病毒和退烧药治疗。结果:第二次访视时,16.7%的老年患者咽喉炎症状完全缓解,无高强度咽喉炎病例。到治疗第3天,这类患者的比例明显增加,达到43.3%,到治疗结束时,96.7%的服用哆里霉素的患者没有喉咙痛。治疗期间最显著的变化是与吞咽不适和吞咽困难等附加症状有关。在评估咽镜图像时,两组在第二次就诊时口咽黏膜充血(p=0.048)和口咽黏膜水肿严重程度(p=0.043)方面差异有统计学意义。接受多柔霉素治疗的患者对治疗的满意度分别为满意和极满意的占33.3%和66.7%,医生评价具有可比性。结论:本研究可提高医生在处方复方药物多orithricin时的信心,该复方药物包括影响老年急性扁桃体咽炎发病机制的所有关键成分的物质,提高患者的满意度和期望值。
[Treatment of acute tonsillopharyngitis in elderly patients: aspects of complex topical therapy].
Introduction: Infectious and inflammatory diseases of the pharynx remain the focus of attention of physicians of many specialties due to their high prevalence and social significance.
Material and methods: The main group (n=30, mean age 68.9±5.6 years) was prescribed Dorithricin for resorption, 1 tablet every 3 hours, no more than 6 tablets per day for 6 days. The control group (n=30, mean age 68.3±4.7 years) was recommended treatment with antiviral and antipyretic agents.
Results: By the 2nd visit, 16.7% of elderly patients experienced complete relief of sore throat, and no cases of high-intensity sore throat were recorded. By the 3rd day of treatment, the proportion of such patients increased significantly, amounting to 43.3%, and by the end of treatment, 96.7% of patients taking Dorithricin had no sore throat. The most significant changes during treatment were noted in relation to such additional symptoms as discomfort when swallowing and dysphagia. When assessing the pharyngoscopic picture, statistically significant differences were noted between the groups by the 2nd visit in relation to hyperemia of the oropharyngeal mucosa (p=0.048), the severity of edema of the oropharyngeal mucosa (p=0.043). Patients who received Dorithricin rated their satisfaction with the treatment as satisfied and extremely satisfied in 33.3% and 66.7%, the assessment of doctors was comparable.
Conclusion: This study may contribute to the confidence of physicians in prescribing the complex drug Dorithricin, which includes substances that affect all key components of the pathogenesis of acute tonsillopharyngitis in elderly patients and increase patient satisfaction and expectations.